Marshall Wace
IMGN

Marshall Wace’s Immunogen Inc IMGN Stock Holding History

Marshall Wace’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,187,027
Closed -$35.2M – 2924
2023
Q4 		$35.2M Buy
+1,187,027
New +$23.6M 0.06% 319
2023
Q2 		– Sell
-114,355
Closed -$439K – 3129
2023
Q1 		$439K Sell
114,355
-114,060
-50% -$486K ﹤0.01% 2155
2022
Q4 		$1.13M Sell
228,415
-7,785
-3% -$42.2K ﹤0.01% 2030
2022
Q3 		$1.13M Buy
+236,200
New +$1.25M ﹤0.01% 2349
2021
Q2 		– Sell
-523,087
Closed -$4.24M – 3236
2021
Q1 		$4.24M Buy
+523,087
New +$4.27M 0.02% 926
2020
Q2 		– Sell
-174,919
Closed -$597K – 2041
2020
Q1 		$597K Buy
174,919
+60,987
+54% +$267K 0.01% 935
2019
Q4 		$582K Buy
+113,932
New +$387K ﹤0.01% 1124
2019
Q3 		– Sell
-144,493
Closed -$314K – 1983
2019
Q2 		$314K Buy
+144,493
New +$342K ﹤0.01% 1174
2019
Q1 		– Sell
-261,608
Closed -$1.26M – 2124
2018
Q4 		$1.26M Buy
+261,608
New +$1.59M 0.01% 849

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Marshall Wace's IMGN Position: Q1 2024 in Review

Marshall Wace sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 1,187,027 shares — an estimated $35.2M sold.

Marshall Wace first reported a position in IMGN in Q4 2018 and held it in 9 quarters. The position peaked at $35.2M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Marshall Wace reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Marshall Wace sold 1,187,027 Immunogen Inc shares in Q1 2024, an estimated $35.2M.
  • Marshall Wace first reported a position in Immunogen Inc in Q4 2018 and held it in 9 quarters.
  • Marshall Wace's Immunogen Inc position peaked at $35.2M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.